C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2026)
C4 Therapeutics' quarterly Depreciation and Depletion came in at $360000.0 in Q1 2026, down 1.1% year-on-year from $364000.0 in Q1 2025, and down 4.51% quarter-over-quarter from $377000.0 in Q4 2025.
C4 Therapeutics has reported Depreciation and Depletion for 7 years, with the latest figure at $360000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation and Depletion fell 1.1% year-over-year to $360000.0; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 10.66% YoY), and the FY2025 full-year result was $1.5 million, up 4.62% from the prior year.
- Depreciation and Depletion for Q1 2026 stood at $360000.0, down from $377000.0 in the prior quarter.
- The five-year high for Depreciation and Depletion was $521000.0 in Q4 2022, with the low at $128000.0 in Q4 2023.
- Average Depreciation and Depletion over 5 years is $382647.1, with a median of $377000.0 recorded in 2025.
- Year-over-year, Depreciation and Depletion plunged 75.43% in 2023 and jumped 184.38% in 2024.
- Tracing CCCC's Depreciation and Depletion over 5 years: stood at $521000.0 in 2022, then sank by 75.43% to $128000.0 in 2023, then jumped by 184.38% to $364000.0 in 2024, then rose by 3.57% to $377000.0 in 2025, then dropped by 4.51% to $360000.0 in 2026.
- The last three Depreciation and Depletion figures came in at $360000.0 (Q1 2026), $377000.0 (Q4 2025), and $384000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | 360,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 360,000.00 |
| Mar 31, 2026 | 360,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Dec 31, 2025 | 377,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 416,000.00 |
| Jun 30, 2025 | 416,000.00 |
| Mar 31, 2025 | 364,000.00 |
| Mar 31, 2025 | 364,000.00 |
| Dec 31, 2024 | 364,000.00 |
| Dec 31, 2024 | 364,000.00 |
| Sep 30, 2024 | 365,000.00 |
| Sep 30, 2024 | 365,000.00 |
| Jun 30, 2024 | 296,000.00 |
| Jun 30, 2024 | 296,000.00 |
| Mar 31, 2024 | 375,000.00 |
| Mar 31, 2024 | 375,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Dec 31, 2023 | 128,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 458,000.00 |
| Jun 30, 2023 | 458,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 521,000.00 |
| Dec 31, 2022 | 521,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Sep 30, 2022 | 415,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Jun 30, 2022 | 435,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Dec 31, 2021 | 323,000.00 |
| Sep 30, 2021 | 330,000.00 |
| Sep 30, 2021 | 330,000.00 |
| Jun 30, 2021 | 388,000.00 |
| Jun 30, 2021 | 388,000.00 |
| Mar 31, 2021 | 451,000.00 |
| Mar 31, 2021 | 451,000.00 |
| Dec 31, 2020 | 365,000.00 |
| Dec 31, 2020 | 365,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Sep 30, 2020 | 420,000.00 |
| Jun 30, 2020 | 416,000.00 |
| Jun 30, 2020 | 416,000.00 |
| Mar 31, 2020 | 416,000.00 |
| Mar 31, 2020 | 416,000.00 |